Sex and age of patients |
Ethnicity of patients |
Administered drug |
Analyzed genes and their polymorphisms |
Associations |
Reference |
Postmenopausal women; NA |
Thai (Asian) |
HRT |
ERα; PvuII
|
P allele: higher increase of
spinal BMD |
[2] |
Postmenopausal women; 47-56 years |
Finnish (Caucasian) |
HRT |
ERα; PvuII
|
P allele: reduced risk of fracture |
[3] |
Postmenopausal women; 40-64 years |
Japanese (Asian) |
HRT |
ERα; 18 intronic SNPs
|
IVS6 + 14144 GG genotype:
higher increase of spinal BMD |
[1] |
Elderly postmenopausal women; 65-77 years |
NA |
HRT |
ERα; PvuII, and XbaI
|
PP and XX genotypes: higher increase of total body, spinal
and femoral BMD |
[4] |
Women; 40-64 years |
Japanese
(Asian) |
HRT |
ERα; PvuII, XbaI
VDR; TaqI, ApaI, FokI |
TT genotype: higher increase
of spinal BMD |
[6] |
Postmenopausal women; 46-54 years |
Turkish (Caucasian) |
HRT |
COL1A1; Sp1 |
SS genotype: higher increase
of spinal and femoral BMD |
[7] |
Postmenopausal osteoporotic women, NA |
Korean
(Asian) |
HRT |
LRP5; A266G, C3893T |
T allele of C3893T: higher risk of non response in terms of lumbar spine and femoral neck BMD gain;
G allele of A266G: higher risk of non response, in terms of lumbar spine BMD gain |
[8] |
Postmenopausal women; NA |
Italian (Caucasian) |
Raloxifene |
VDR; BsmI
|
BB genotype: higher increase of
spinal BMD
|
[9] |
Postmenopausal women; NA |
Brazilian |
Raloxifene |
ERα; PvuII, XbaI |
PP and xx genotypes: better lumbar spine BMD response |
[10] |
Postmenopausal women; 56-73 years |
Slovenian (Caucasian) |
Etidronate |
VDR; BsmI
|
bb genotype: lower increase
of spinal BMD |
[11] |
Postmenopausal women; NA |
Italian (Caucasian) |
Five treatment groups:
1) Alendronate plus raloxifene
2) Alendronate plus HRT
3) Alendronate alone
4) HRT alone
5) Raloxifene alone |
VDR; BsmI
|
bb genotype: lower increase
of spinal BMD |
[12] |
Early postmenopausal women; NA |
NA |
Etidronate |
COL1A1; Sp1
|
SS genotype: higher increase
of femoral BMD |
[13] |
Postmenopausal osteoporotic women; NA |
Chinese
(Asian) |
Alendronate |
OPG; A163G, T245G, T950C |
G allele of A163G: lower increase at vertebral L2-4, inter-troche and total hip BMD.
G allele of T245G:lower increase at vertebral L2-4, inter-troche and total hip BMD. |
[16] |
